CSL Ltd
F:CSJA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
CSL Ltd
F:CSJA
|
AU |
|
C
|
CSL Ltd
XMUN:CSJ
|
AU |
|
J
|
J.M. Smucker Co
F:JM2
|
US |
|
S
|
Saipem SpA
F:SPEA
|
IT |
Intrinsic Value
Is CSJA undervalued or overvalued?
See the intrinsic value estimate for 
CSL Ltd and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What CSL Does
CSL Ltd is a global biopharmaceutical company that makes medicines from human plasma and other biological materials. Its main products are treatments for immune disorders, bleeding disorders, and other serious conditions, plus vaccines for influenza and related infectious diseases. The company also sells iron and kidney-care therapies through its specialty medicines business.
- Headquarters
- Australia AU
- Employees
- 32 065
- IPO date
- Jun 8, 1994
CSL has no economic moat
Established rivals can supply competing plasma medicines, while generic alternatives limit protection for parts of CSL’s iron treatment business. CSL’s manufacturing expertise and product approvals create hurdles, but do not by themselves keep capable competitors from pursuing its customers and profits.
Read the full moat analysis
Earnings Waterfall
CSL Ltd
The intrinsic value for CSL Ltd (CSJA) under the Base Case is hidden EUR.
Compared with the current market price of 30.4 EUR, the stock appears hidden.
